Minimal Dose CT Identifies Lung Tumors Earlier

Lung cancer is associated with very high mortality, partly because it is difficult to find at early stages, but also because it can recur frequently after surgical removal. The question arises as to what is the best way to follow lung cancer patients after surgery to target problems early enough, before symptoms become apparent, so that patients may still be eligible for new interventions.

The study’s findings were presented May 8, 2013, at the 93rd American Association for Thoracic Surgery (AATS) annual meeting, held in Minneapolis (MN, USA). “Up to a few years ago, we were using chest X-rays to monitor patients after surgery for lung cancer, but this follow-up was ineffective, and many patients still died of recurrent lung cancer, noted lead investigator Waël C. Hanna, MDCM, MBA, from the department of thoracic surgery at the University of Toronto (ON, Canada). “While CT scans can effectively be used to monitor lung cancer after surgery, there was significant concern about the large amount of radiation that will be delivered to patients, and standard dose CT scans were not used routinely in the follow-up of lung cancer. More recently, new technology allowed us to develop MnDCT.”

As reported in this study, most of new or recurrent cancer was identified by MnDCT at a subclinical, intrathoracic stage, within two years of surgery. This allowed for the delivery of curative treatment in the majority of patients with asymptomatic cancer and was associated with long survival.

The study tracked 271 patients with lung cancer (80% stage I, 12.5% stage II) who underwent curative resection of lung cancer. Repeated imaging occurred at 3, 6, 12, 18, 24, 36, 48, and 60 months using both conventional chest X-rays and MnDCT scans. Investigators revealed that MnDCT detected 94% of recurrent cancers compared to only 21% with standard X-rays (p < 0.0001). Significantly, the recurrent lung cancer was detected at a much earlier stage, allowing patients to feasibly undergo another curative surgery.

Identification of a new or recurrent tumor in asymptomatic patients led to additional surgery or radiation for 75.5%, while palliative treatment was recommended for the remainder of patients. Survival in the treated group was considerably longer than those who were treated with palliative intent (69 months vs. 15 months, p < 0.0001).


“MnDCT offers the best of both worlds: on the one hand it allows for precise imaging close to what is produced from a standard CT scan, and on the other hand it only delivers a small amount of radiation which is comparable to what a regular X-ray would deliver and much less than a standard dose CT scan,” said Dr. Hanna. “More importantly, now we can detect recurrent lung cancer at a much earlier stage, allowing patients to possibly undergo another surgery, and live longer, healthier lives.”

The study did find that MnDCT findings generated a high rate of false-positives, and the need for surgeons to be alert to this limitation in order to make correct clinical judgments regarding follow-up treatment.

Related Links:
University of Toronto